METTL3 and metabolic dysfunction-associated steatotic liver disease: In non-alcoholic fatty liver disease-hepatocellular carcinoma (NAFLD-HCC), METTL3 enhances m6A methylation on the mRNA of sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP), promoting its translation and activating cholesterol biosynthesis.